Cargando…
Comment on Afshar-Oromieh et al.: PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
Autores principales: | Reske, Sven Norbert, Winter, Gordon, Baur, Benjamin, Machulla, Hans-Jürgen, Kull, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644208/ https://www.ncbi.nlm.nih.gov/pubmed/23558687 http://dx.doi.org/10.1007/s00259-013-2385-z |
Ejemplares similares
-
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
por: Baur, Benjamin, et al.
Publicado: (2014) -
Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
por: Lawhn-Heath, Courtney, et al.
Publicado: (2020) -
(68)Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer
por: Zhang, Jiaying, et al.
Publicado: (2022) -
Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023) -
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)